Jafron Short Long Term Debt from 2010 to 2024

300529 Stock   30.48  0.41  1.36%   
Jafron Biomedical's Short and Long Term Debt is increasing over the years with slightly volatile fluctuation. Short and Long Term Debt is expected to dwindle to about 212.3 M. Short and Long Term Debt is the total of a company's short-term and long-term borrowings. View All Fundamentals
 
Short and Long Term Debt  
First Reported
2010-12-31
Previous Quarter
261.8 M
Current Value
212.3 M
Quarterly Volatility
111 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jafron Biomedical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jafron Biomedical's main balance sheet or income statement drivers, such as Interest Expense of 57 M, Selling General Administrative of 363.6 M or Total Revenue of 1.2 B, as well as many indicators such as . Jafron financial statements analysis is a perfect complement when working with Jafron Biomedical Valuation or Volatility modules.
  
This module can also supplement various Jafron Biomedical Technical models . Check out the analysis of Jafron Biomedical Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jafron Stock

Jafron Biomedical financial ratios help investors to determine whether Jafron Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Jafron with respect to the benefits of owning Jafron Biomedical security.